News | November 01, 2021
Dr Reddys Laboratories posts Q2FY22 PAT at Rs 992 Cr
Dr. Reddy's Laboratories has reported consolidated financial results for the period ended September 30, 2021
Dr. Reddy's Laboratories has reported consolidated financial results for the period ended September 30, 2021
The company is a medical dictation solution used by medical practitioners
It is the first U.S. FDA approved novel topical mechanism for acne in nearly 40 years
_256_384.jpg)
Both parties are expected to invest a total of US $ 1 million to establish the brand
The release of this batch will secure the supply for hospitals and cancer centres that are involved in the clinical trials managed by the company
The acquisition expands Takeda’s immuno-oncology and innate immune cell therapy portfolio with novel platforms leveraging T cells for the potential treatment of solid tumours and haematological malignancies
The collaboration provides KardiaMobile users quick access to doctors worldwide for consultations about their ECG readings
Two leaders in science combine complementary best-in-class technologies for biologics manufacturing customers
It launched the most advanced "DTAS" (Direct to Angio Suite) & State of the art ‘Neuro-Angio’ technology
Laurus Labs Limited has reported consolidated financial results for the period ended September 30, 2021
Subscribe To Our Newsletter & Stay Updated
